Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 6/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.38 |
| ▸ | AR | P10275 | 6/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22853404 | 0.73 | TAS2R14 (0.43) | TAS2R14PRKCQPRKCDAR | |
| SCHEMBL17197622 | 0.71 | TAS2R14 (0.52) | TAS2R14AR | |
| SCHEMBL24155090 | 0.71 | TAS2R14 (0.40) | TAS2R14PRKCQPRKCDAR | |
| SCHEMBL25850487 | 0.71 | TAS2R14 (0.40) | TAS2R14PRKCQPRKCDAR | |
| SCHEMBL22833433 | 0.70 | TAS1R3 (0.44) | TAS2R14AR | |
| SCHEMBL22853405 | 0.70 | TAS1R3 (0.44) | TAS2R14AR | |
| SCHEMBL30294636 | 0.70 | TAS1R3 (0.44) | TAS2R14AR | |
| SCHEMBL495787 | 0.68 | NOS2 (0.40) | — | |
| SCHEMBL496028 | 0.68 | TAS2R14 (0.42) | TAS2R14AR | |
| SCHEMBL496533 | 0.68 | TAS2R14 (0.42) | TAS2R14AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| CN-101312720-A | 2-aminobenzamide derivative | ASTELLAS PHARMA INC (JP) | 2008-11-26 | — | — | CN | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | PKM 4591/4885TAS2R14 607/4885PRKCQ 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.